Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
Plitidepsin is a cyclic peptide that inhibits the host protein elongation factor alpha 1, thus blocking viral replication. A hospitalized patient with stage IIIB gastric signet ring cell carcinoma and multiple comorbidities developed Coronavirus disease (COVID-19) shortly after receiving his first chemotherapy course. He was treated with plitidepsin on a compassionate use basis. The patient showed a substantial acute reduction in viral load 4 days after initiating plitidepsin treatment and was negative for SARS-CoV-2 by day 14. Therapy was well-tolerated, and no COVID-19-related complications were observed. The patient was discharged 18 days after plitidepsin treatment having received a full second course of chemotherapy, with only a 1-week delay from the planned schedule.
Annals of Oncology , commentaire en libre accès, 2021